These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
168 related items for PubMed ID: 21281749
1. Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD). Manghat P, Souleimanova I, Cheung J, Wierzbicki AS, Harrington DJ, Shearer MJ, Chowienczyk P, Fogelman I, Nerlander M, Goldsmith D, Hampson G. Bone; 2011 May 01; 48(5):1127-32. PubMed ID: 21281749 [Abstract] [Full Text] [Related]
2. Circulating sclerostin and Dickkopf-1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Thambiah S, Roplekar R, Manghat P, Fogelman I, Fraser WD, Goldsmith D, Hampson G. Calcif Tissue Int; 2012 Jun 01; 90(6):473-80. PubMed ID: 22527202 [Abstract] [Full Text] [Related]
3. The relationship between intact PTH and biointact PTH (1-84) with bone and mineral metabolism in pre-dialysis chronic kidney disease (CKD). O'Flaherty D, Sankaralingam A, Scully P, Manghat P, Goldsmith D, Hampson G. Clin Biochem; 2013 Oct 01; 46(15):1405-9. PubMed ID: 23830844 [Abstract] [Full Text] [Related]
4. Clinical significance of bone alkaline phosphatase isoforms, including the novel B1x isoform, in mild to moderate chronic kidney disease. Haarhaus M, Fernström A, Magnusson M, Magnusson P. Nephrol Dial Transplant; 2009 Nov 01; 24(11):3382-9. PubMed ID: 19542194 [Abstract] [Full Text] [Related]
5. Bone markers predict cardiovascular events in chronic kidney disease. Fahrleitner-Pammer A, Herberth J, Browning SR, Obermayer-Pietsch B, Wirnsberger G, Holzer H, Dobnig H, Malluche HH. J Bone Miner Res; 2008 Nov 01; 23(11):1850-8. PubMed ID: 18597636 [Abstract] [Full Text] [Related]
6. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Nephrol Dial Transplant; 2008 Feb 01; 23(2):586-93. PubMed ID: 17933842 [Abstract] [Full Text] [Related]
7. Total and bone-specific alkaline phosphatase are associated with bone mineral density over time in end-stage renal disease patients starting dialysis. Bergman A, Qureshi AR, Haarhaus M, Lindholm B, Barany P, Heimburger O, Stenvinkel P, Anderstam B. J Nephrol; 2017 Apr 01; 30(2):255-262. PubMed ID: 26994005 [Abstract] [Full Text] [Related]
8. Increased undercarboxylated osteocalcin/intact osteocalcin ratio in patients undergoing hemodialysis. Nagata Y, Inaba M, Imanishi Y, Okazaki H, Yamada S, Mori K, Shoji S, Koyama H, Okuno S. Osteoporos Int; 2015 Mar 01; 26(3):1053-61. PubMed ID: 25403902 [Abstract] [Full Text] [Related]
9. Fibroblast growth factor-23 is associated with C-reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Manghat P, Fraser WD, Wierzbicki AS, Fogelman I, Goldsmith DJ, Hampson G. Osteoporos Int; 2010 Nov 01; 21(11):1853-61. PubMed ID: 20012018 [Abstract] [Full Text] [Related]
10. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism. Lu KC, Ma WY, Yu JC, Wu CC, Chu P. Clin Endocrinol (Oxf); 2012 May 01; 76(5):634-42. PubMed ID: 22007930 [Abstract] [Full Text] [Related]
11. The relationship between inhibitors of the Wnt signalling pathway (Dickkopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Hampson G, Edwards S, Conroy S, Blake GM, Fogelman I, Frost ML. Bone; 2013 Sep 01; 56(1):42-7. PubMed ID: 23702386 [Abstract] [Full Text] [Related]
12. Bone mineral density and biochemical markers of bone metabolism in predialysis patients with chronic kidney disease. Fidan N, Inci A, Coban M, Ulman C, Kursat S. J Investig Med; 2016 Apr 01; 64(4):861-6. PubMed ID: 26969749 [Abstract] [Full Text] [Related]
13. Bone turnover markers are associated with bone density, but not with fracture in end stage kidney disease: a cross-sectional study. Jørgensen HS, Winther S, Bøttcher M, Hauge EM, Rejnmark L, Svensson M, Ivarsen P. BMC Nephrol; 2017 Sep 06; 18(1):284. PubMed ID: 28874132 [Abstract] [Full Text] [Related]
14. Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Magnusson P, Sharp CA, Magnusson M, Risteli J, Davie MW, Larsson L. Kidney Int; 2001 Jul 06; 60(1):257-65. PubMed ID: 11422759 [Abstract] [Full Text] [Related]
15. Relationship between biochemical markers and radial cortical bone changes in hemodialysis patients. Fujimori A, Okada S, Sakai M, Tome K, Fukagawa M. Nephron Clin Pract; 2011 Jul 06; 118(4):c375-9. PubMed ID: 21325869 [Abstract] [Full Text] [Related]
16. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation. Avbersek-Luznik I, Gmeiner Stopar T, Marc J. Clin Chem Lab Med; 2007 Jul 06; 45(8):1014-8. PubMed ID: 17579570 [Abstract] [Full Text] [Related]
17. [Relationship between coronary and abdominal calcification score, serum osteoprotegerin (OPG), and serum tartrate-resistant acid phosphatase (TRACP) -5b in pre-dialysis CKD patients]. Shiota J, Izumi N, Kasahara H, Tagawa H, Chiba T, Nihei H. Nihon Jinzo Gakkai Shi; 2010 Jul 06; 52(8):1022-8. PubMed ID: 21254698 [Abstract] [Full Text] [Related]
18. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. Bielesz BO, Hecking M, Plischke M, Cejka D, Kieweg H, Haas M, Marculescu R, Hörl WH, Bieglmayer C, Sunder-Plassmann G. Clin Biochem; 2014 Sep 06; 47(13-14):1316-9. PubMed ID: 24956265 [Abstract] [Full Text] [Related]
19. FGF-23 and osteoprotegerin are independently associated with myocardial damage in chronic kidney disease stages 3 and 4. Another link between chronic kidney disease-mineral bone disorder and the heart. Ford ML, Smith ER, Tomlinson LA, Chatterjee PK, Rajkumar C, Holt SG. Nephrol Dial Transplant; 2012 Feb 06; 27(2):727-33. PubMed ID: 21750158 [Abstract] [Full Text] [Related]